One approach to address this problem is to use dual-targeting CAR T cells, as observed in clinical trials using CAR T cells targeting CD19/CD22 for leukemia and lymphoma, CD19/CD20 for lymphoma, and BCMA/CD38 for MM11–15. Here, CD22 is linked to lymphoma.